Entrovas-24/26 Tablet

Entrovas-24/26 Tablet সম্পর্কে

Entrovas-24/26 হলো Sacubitril + Valsartan-এর একটি ব্র্যান্ড, শক্তি ২৪ mg + ২৬ mg, ট্যাবলেট আকারে। Entrovas-24/26-এর সাথে Sacubitril + Valsartan-এর অন্য ব্র্যান্ডের দাম নিচে তুলনা করে দেখুন। এটি তৈরি করে Renata PLC। ডাক্তারের প্রেসক্রিপশন মেনে চলুন এবং অন্য ব্র্যান্ড খাওয়া যাবে কি না তা ফার্মাসিস্টের কাছ থেকে জেনে নিন।

Sacubitril + Valsartan-এর ২৫টি ব্র্যান্ড বাংলাদেশে তালিকাভুক্ত। সবচেয়ে কম দাম Arnis 24 mg+26 mg Tablet-এর, প্রতি ইউনিট ৳ ৩৫.০০।

Entrovas-24/26 Tablet কী?

Entrovas-24/26 is a tablet made by Renata PLC. that contains sacubitril and valsartan. It belongs to a group of heart-failure medicines that act in two ways at once: sacubitril raises the level of natural peptides the body makes that help widen blood vessels and clear fluid, while valsartan blocks the action of angiotensin II, a substance that tightens blood vessels. Together they ease the workload on a failing heart. It is prescribed for long-term heart failure with reduced pumping ability, and for some children with symptomatic heart failure. Only a doctor can decide whether it suits a particular person.

Entrovas-24/26-এর ব্যবহার

Entrovas-24/26 is used to lower the risk of cardiovascular death and hospital admission in adults with long-term heart failure and reduced ejection fraction. It is also used for symptomatic heart failure with poor left-sided pumping in children aged one year and older. It is not a general blood-pressure tablet for everyone; the doctor decides whether it is appropriate.

Entrovas-24/26 কীভাবে ব্যবহার করবেন

Take Entrovas-24/26 exactly as the doctor prescribes. The doctor chooses the starting dose and any later change, and decides how long the course lasts. Swallow the tablet as directed by your doctor or pharmacist. Do not stop or change the medicine on your own, even if you feel better, and ask your doctor before taking any other medicine alongside it.

Entrovas-24/26-এর পার্শ্বপ্রতিক্রিয়া

Side effects that need attention include swelling of the face, lips, tongue or throat (angioedema), low blood pressure with dizziness or fainting, worsening kidney function, raised potassium, cough and dizziness. Contact your doctor promptly if you notice swelling, trouble breathing, fainting, or a big drop in urine. Ask your doctor or pharmacist about anything that worries you.

সতর্কতা ও নিরাপত্তা

Tell your doctor about any previous swelling of the face, lips or throat, especially linked to heart or blood-pressure medicines, and about kidney or liver problems. This medicine is not used together with certain other heart and blood-pressure drugs, so give your doctor a full list of what you take. It is not recommended in severe liver impairment. Use in pregnancy should be discussed with the doctor first, and children under one year are not covered. Ask your doctor before use if you are pregnant, planning pregnancy or breastfeeding.

সাধারণ প্রশ্ন

What kind of medicine is Entrovas-24/26 and what is it used for?

It is a tablet combining sacubitril and valsartan, used for long-term heart failure with reduced pumping ability, and for some children with symptomatic heart failure. The doctor decides if it is suitable for you.

What side effects should I watch for and when should I call the doctor?

Watch for swelling of the face, lips, tongue or throat, fainting, strong dizziness, or much less urine than usual. Call your doctor promptly if any of these happen, or if you feel unwell after starting the medicine.

What does the generic name sacubitril plus valsartan mean?

Sacubitril is a neprilysin inhibitor, meaning it slows the breakdown of natural peptides that help the heart and blood vessels. Valsartan is an angiotensin receptor blocker, which stops angiotensin II from tightening blood vessels. The tablet combines both actions.

Can I stop Entrovas-24/26 on my own or take other medicines with it?

Do not stop or change it without your doctor. Some medicines, including certain heart, blood-pressure and pain medicines, should not be combined with it. Give your doctor and pharmacist a full list of everything you take before adding anything new.

নির্দেশনা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

This is indicated:
  • To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
  • For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
  • ... Read more
This is indicated:
  • To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
  • For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
  • This is usually administered in conjunction with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB.

ফার্মাকোলজি

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

This tablet contains a neprilysin inhibitor, sacubitril, and an angiotensin receptor blocker, valsartan. This tablet inhibits neprilysin (neutral endopeptidase; NEP) via LBQ657, the active metabolite of the prodrug sacubitril, and blocks the angiotensin II type-1 (AT1 ) receptor via valsartan. The cardiovascular and renal effects of this tablet in heart failure patients are attributed to the increased levels of peptides that are degraded by neprilysin, such as natriuretic peptides, by LBQ657, and the simultaneous inhibition of the effects of angiotensin II by valsartan. Valsartan inhibits the effects of angiotensin II by selectively blocking the AT1 receptor, and also inhibits angiotensin II-dependent aldosterone release.

মাত্রা ও সেবনবিধি

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Adult Heart Failure: The recommended starting dose is 49/51 mg orally twice daily. Double the dose after 2 to 4 weeks to the target maintenance dose of 97/103 mg twice daily, as tolerated by the patient.

Reduce the starting dose to 24/26 mg twice daily for:
  • Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents.
  • Patients with severe renal impairment.
  • Patients with moderate hepatic impairment.
Pediatric Heart Failure: Refer to Table 1 for the recommended dose for pediatric patients aged one year and older. Take the recommended dose orally twice daily. Adjust pediatric patient doses every 2 weeks, as tolerated by the patient.

Recommended Dose Titration-

Pediatric Patients Less than 40 kg:
  • Starting: 1.6 mg/kg
  • Second: 2.3 mg/kg
  • Final: 3.1 mg/kg
Pediatric Patients At least 40 kg, less than 50 kg:
  • Starting: 24/26 mg
  • Second: 49/51 mg
  • Final: 49/51 mg
Pediatric Patients At least 50 kg:
  • Starting: 49/51 mg
  • Second: 72/78 mg
  • Final: 97/103 mg

ঔষধের মিথষ্ক্রিয়া

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Dual Blockade of the Renin-Angiotensin-Aldosterone System: Should not be used with an ACEi, aliskiren in patients with diabetes, and use with an ARB should be avoided.
Potassium-sparing Diuretics: Serum potassium level may be increased.
NSAIDs: Risk of renal impairment may be increased.
Lithium: Increased risk of lithium toxicity.

প্রতিনির্দেশনা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

This combination is contraindicated:
  • In patients with hypersensitivity to any component
  • In patients with a history of angioedema related to previous ACE inhibitor or ARB therapy 
  • With concomitant use of ACE inhibitors. Do not administer within 36 hours of switching from or to an ACE inhibitor 
  • With concomitant use of aliskiren in patients with diabetes

পার্শ্ব প্রতিক্রিয়া

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

The most common side effects are Angioedema, Hypotension, Impaired Renal Function, Hyperkalemia, Cough, Dizziness.

গর্ভাবস্থায় ও স্তন্যদানকালে

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Pediatric Use: Safety and effectiveness have not been established in pediatric patients less than 1 year of age.

Geriatric Use: No relevant pharmacokinetic differences have been observed in elderly (>65 years) or very elderly (>75 years) patients compared to the overall population.
 
Hepatic Impairment: No dose adjustment is required when administering this tablet to patients with mild hepatic impairment (Child-Pugh A classification). This tablet is not recommended in patients with severe hepatic impairment, as no studies have been conducted in these patients.

Renal Impairment: No dose adjustment is required in patients with mild (eGFR 60 to 90 ml/min/1.73 m2) to moderate (eGFR 30 to 60 ml/min/1.73 m2) renal impairment. The recommended starting dose in patients with severe renal impairment (eGFR <30 ml/min/1.73 m2) is 24/26 mg twice daily.

সতর্কতা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

This tablet may cause angioedema and must not be used in patients with a known history of angioedema related to previous ACEi or ARB therapy and in patients with hereditary angioedema.

This tablet lowers blood pressure and may cause symptomatic hypotension. Closely monitor serum creatinine, and down-titrate or interrupt this tablet in patients who develop a clinically significant decrease in renal function. In patients with renal artery stenosis, monitor renal function.

Monitor serum potassium periodically and treat appropriately, especially in patients with risk factors for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism, or a high potassium diet. Dosage reduction or interruption of this tablet may be required.

মাত্রাধিক্যতা

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Limited data are available with regard to overdosage in human subjects with this tablet. In healthy volunteers, a single dose of this tablet 583 mg sacubitril/617 mg valsartan, and multiple doses of 437 mg sacubitril/463 mg valsartan (14 days) have been studied and were well tolerated. Hypotension is the most likely result of overdosage due to the blood-pressure-lowering effects of this tablet. Symptomatic treatment should be provided. This tablet is unlikely to be removed by hemodialysis because of high protein binding.

সংরক্ষণ

এই লেখার বাংলা এখনো নেই; ইংরেজি লেখা দেখানো হচ্ছে।

Keep in a dry place and store below 30°C. Protect from moisture and keep out of the reach of children.

বিকল্প ব্র্যান্ড: Sacubitril + Valsartan

একই জেনেরিকের অন্য ব্র্যান্ড, কম দাম আগে।

Arnis Tablet

24 mg+26 mg

Sacubitril + Valsartan

Eskayef Pharmaceuticals Ltd.

৳ ৩৪.৩ ৳ ৩৫.০০ ২% ছাড় প্রতি ইউনিট

Covista 50 Tablet

24 mg + 26 mg

Sacubitril + Valsartan

Advanced Chemical Industries PLC

৳ ৪১.১৬ ৳ ৪২ ২% ছাড় প্রতি ইউনিট

Arnigen Tablet

24 mg+26 mg

Sacubitril + Valsartan

General Pharmaceuticals Ltd.

৳ ৪৪.১ ৳ ৪৫.০০ ২% ছাড় প্রতি ইউনিট

Arnivas Tablet

24 mg+26 mg

Sacubitril + Valsartan

Opsonin Pharma Ltd.

৳ ৪৪.১ ৳ ৪৫.০০ ২% ছাড় প্রতি ইউনিট

Valmor 50 Tablet

24 mg + 26 mg

Sacubitril + Valsartan

Square Pharmaceuticals PLC.

৳ ৪৪.১ ৳ ৪৫ ২% ছাড় প্রতি ইউনিট

Arnis Tablet

49 mg+51 mg

Sacubitril + Valsartan

Eskayef Pharmaceuticals Ltd.

৳ ৬৮.৬ ৳ ৭০.০০ ২% ছাড় প্রতি ইউনিট

Covista 100 Tablet

49 mg + 51 mg

Sacubitril + Valsartan

Advanced Chemical Industries PLC

৳ ৭৬.৪৪ ৳ ৭৮ ২% ছাড় প্রতি ইউনিট

Arnivas Tablet

49 mg+51 mg

Sacubitril + Valsartan

Opsonin Pharma Ltd.

৳ ৭৮.৪ ৳ ৮০.০০ ২% ছাড় প্রতি ইউনিট

Arnigen Tablet

49 mg+51 mg

Sacubitril + Valsartan

General Pharmaceuticals Ltd.

৳ ৮৩.৩ ৳ ৮৫.০০ ২% ছাড় প্রতি ইউনিট

Arnigen Tablet

97 mg+103 mg

Sacubitril + Valsartan

General Pharmaceuticals Ltd.

৳ ১১৭.৬ ৳ ১২০.০০ ২% ছাড় প্রতি ইউনিট

সব দেখুন ২৫ ব্র্যান্ড

ঔষধের তথ্য শুধু জানার জন্য, এটি চিকিৎসা পরামর্শ নয়। সবসময় ডাক্তারের প্রেসক্রিপশন মানুন এবং ফার্মাসিস্টের সাথে কথা বলুন।